Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




RBC Distribution Width Associated with COVID-19 Mortality Risk

By LabMedica International staff writers
Posted on 06 Oct 2020
COVID-19 has a high rate of hospitalization, critical care requirement, and mortality. More...
Identifying patients at highest risk for severe disease is important to facilitate early, aggressive intervention and to manage local hospital resources to mitigate the critical care crises that have impacted some hospital systems.

The red blood cell distribution width (RDW) is a standard component of a routine complete blood count test. Elevated RDW is associated with an increased risk for all-cause mortality; mortality from heart disease, pulmonary disease, sepsis, influenza, and cancer; complications associated with heart failure, severity of coronary artery disease and viral hepatitis, advanced stage and grade for many cancers.

A team of Medical Scientists at the Massachusetts General Hospital (Boston, MA, USA) retrospectively analyzed for 1,641 patients’ data who tested positive for SARS-CoV-2 infection between March 4, 2020, and April 28, 2020. Participants in the study had a mean age of 62 years, 54% were men, 45% were White individuals and 30% Hispanic, and 17% of patients in the cohort died.

For all inpatients, RDW, absolute lymphocyte count, and D-dimer level were collected approximately daily along with other clinical laboratory values, as part of standard clinical care. Complete blood counts, including RDW and lymphocyte count were performed on an XN-9000 Automated Hematology System (Sysmex Corporation, Kobe, Japan). D-dimer level was measured using a Vidas 3 immunoanalyzer (bioMérieux, Marcy-l'Étoile, France).

The team reported that patients whose RDW was greater than 14.5% at admission for a COVID-19 diagnosis had a mortality risk of 31%, whereas those with an RDW of 14.5% or less had a mortality risk of 11%. The relative risk (RR) of mortality for those with an elevated RDW was 2.73. In patient groups stratified by age, elevated RDW remained associated with increased RR of mortality for patients younger than 50 years, 50 to 59 years, 60 to 69 years, and 80 years or older. The study found that patients with elevated RDW at admission were 6.12 times more likely to die within 48 hours, 23/470 (4.9%) patients than patients with a normal RDW, 9/1175 (0.8%) patients.

An increasing RDW during hospitalization was linked to a greater risk of death than if RDW did not change. The mortality risk jumped from 6% to 24% for those with a normal RDW at admission, and from 22% to 40% for those with an elevated RDW when they were admitted. The association was also independent of D-dimer levels, absolute lymphocyte count, demographic factors, and common comorbidities

The authors concluded that in this cohort study of patients hospitalized for COVID-19, RDW measured at admission and during hospitalization was associated with a statistically significant increase in mortality. RDW is a routine laboratory test that may be useful in risk stratification of hospitalized patients with COVID-19. The study was published on September 23, 2020 in the journal JAMA Network Open.

Related Links:
Massachusetts General Hospital
Sysmex Corporation
bioMérieux



New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Portable Electronic Pipette
Mini 96
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
New
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Left is the original cell image and right is same cell image zoomed in and rendered in the special imaging software (Photo courtesy of FIU)

Brain Inflammation Biomarker Detects Alzheimer’s Years Before Symptoms Appear

Alzheimer’s disease affects millions globally, but patients are often diagnosed only after memory loss and other symptoms appear, when brain damage is already extensive. Detecting the disease much earlier... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.